Kenneth Kirk, MD
Geriatric Medicine · Tulsa, OKNPI 1073521332
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AstraZeneca at 31.8% of the total. Reporting peaked in 2022 at $689 and has fallen 97.4% since, to $18 in 2025. Among geriatric medicine clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $15.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$568
- Novo Nordisk$343
- AbbVie$235
- Boehringer Ingelheim$140
- Lilly USA, LLC$103
- Alkermes, Inc.$71
- plus $325 from 10 others
What the payments were for
- Food & beverage$1,784100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $568 |
| Novo Nordisk | 22 | $343 |
| AbbVie | 19 | $235 |
| Boehringer Ingelheim | 10 | $140 |
| Lilly USA, LLC | 6 | $103 |
| Alkermes, Inc. | 4 | $71 |
| Pfizer | 4 | $67 |
| GSK | 4 | $56 |
| Collegium Pharmaceutical, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Johnson & Johnson | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
How this compares
$1,784 in reported general payments places this provider in the 90th percentile of 25 geriatric medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,643 | $51,825 |
| BelbucaBuprenorphine Hcl | 55 | $44,489 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,475 | $44,135 |
| Buprenorphine | 143 | $41,534 |
| Xtampza ErOxycodone Myristate | 64 | $30,792 |
| VraylarCariprazine Hcl | 17 | $25,895 |
| Oxycodone Hcl | 788 | $15,777 |
| MounjaroTirzepatide | 12 | $12,873 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $12,735 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 46 | $8,872 |
| Buprenorphine Hcl | 249 | $8,530 |
| Morphine Sulfate ErMorphine Sulfate | 279 | $8,299 |
| BelsomraSuvorexant | 18 | $7,895 |
| Pregabalin | 503 | $7,184 |
| Morphine Sulfate | 82 | $2,479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $39 | $75,281119 claims |
| AbbVieVraylar | $235 | $25,89517 claims |
| Lilly USA, LLCMounjaro | $103 | $12,87312 claims |
| GSKTrelegy Ellipta | $56 | $12,73518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 25 geriatric medicine providers in Oklahoma.
Other geriatric medicine in Tulsa
- Insung KimTulsa$7K
- Lisa DuckettTulsa$629
- David KraftTulsa$512
- Chandini SharmaTulsa$254
- John CarmentTulsa$43
- Larry BalzerEdmond$2K
- Laurence RubensteinOklahoma City$2K
- Padmashree VeluryLawton$1K
- Madison AndrewsOklahoma City$489
- Karen RossOklahoma City$438
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.